 | |
| Clinical data | |
|---|---|
| Trade names | Viekira Pak (in combination with ombitasvir, ritonavir and dasabuvir), Technivie/Viekirax (in combination with ombitasvir and ritonavir) |
| Other names | Veruprevir; ABT-450 |
| License data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | was not evaluated |
| Protein binding | 97–98.6% |
| Metabolism | Hepatic, CYP3A4 and CYP3A5 |
| Onset of action | 4 to 5 hours |
| Elimination half-life | 5.5 hours |
| Excretion | feces (88%), urine (8,8%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C40H43N7O7S |
| Molar mass | 765.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Paritaprevir (previously known as ABT-450) is an acylsulfonamide[1] inhibitor of the NS3-4A serine protease[2] manufactured by Abbott Laboratories[3] that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1.[4] Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.[5]: 248
Paritaprevir was a component of Viekira Pak and Technivie.[6] In May 2018, the FDA announced that Technivie and Viekira were to be discontinued. The discontinuation was voluntary and not related to the safety, quality, or efficacy of the medicine. It was estimated that both medications would be available until January 1, 2019.[7]
YouTube Encyclopedic
-
1/2Views:1 0141 754
-
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100%...
-
Pharma Tube - 88 - Chemotherapy - 11 - Antiviral Drugs - Part 2 (Hepatitis Viruses)
Transcription
References
- ^ Tan SL, He Y, eds. (2011). Hepatitis C: antiviral drug discovery and development. Norfolk: Caister academic press. p. 210. ISBN 9781904455783. Retrieved 28 April 2014.
- ^ Jensen D, Reau N, eds. (2013). Hepatitis C. New York: Oxford University Press. p. 144. ISBN 9780199844296. Retrieved 28 April 2014.
- ^ "Abbott Announces Phase 3 Hepatitis C Program Details". Abbott company website. Abbott Laboratories. Retrieved 28 April 2014.
- ^ Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. (January 2014). "Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1". The New England Journal of Medicine. 370 (3): 222–32. doi:10.1056/NEJMoa1306227. PMID 24428468.
- ^ Lange C, Sarrazin C (2013). "Hepatitis C: New Drugs". In Mauss S, Berg T, Rockstroh J, Sarrazin C (eds.). Hepatology 2013 a clinical textbook (PDF) (4th ed.). Düsseldorf: Flying Publisher. ISBN 978-3-924774-90-5. Archived from the original (PDF) on 29 April 2014. Retrieved 28 April 2014.
- ^ "TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Archived from the original (PDF) on 7 August 2015. Retrieved 28 July 2015.
- ^ "Current and Resolved Drug Shortages and Discontinuations Reported to FDA".
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 20 December 2023, at 19:28